CRISPR Therapeutics AG (CRSP) Other Working Capital Changes (2015 - 2026)

CRISPR Therapeutics AG has disclosed Other Working Capital Changes across 12 years of filings, most recently posting $247000.0 for Q1 2026.

• Other Working Capital Changes for Q1 2026 came in at $247000.0, up 129.98% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.3 million (changed 0.13% YoY), and the FY2025 annual result was -$3.3 million, down 71.22% from the prior year.
• Other Working Capital Changes came in at $247000.0 for Q1 2026 at CRISPR Therapeutics AG, up from -$3.9 million in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $22.6 million in Q4 2023 to a low of -$16.8 million in Q3 2023.
• The 5-year median for Other Working Capital Changes is -$212000.0 (2025), against an average of -$15058.8.
• Peak annual rise in Other Working Capital Changes reached 9161.45% in 2023, while the deepest fall reached 1420.39% in 2023.
• CRISPR Therapeutics AG's Other Working Capital Changes stood at -$249000.0 in 2022, then soared by 9161.45% to $22.6 million in 2023, then tumbled by 85.99% to $3.2 million in 2024, then sank by 221.9% to -$3.9 million in 2025, then surged by 106.41% to $247000.0 in 2026.
• The last three Other Working Capital Changes figures came in at $247000.0 (Q1 2026), -$3.9 million (Q4 2025), and -$212000.0 (Q3 2025), per Business Quant data.